The federal lawsuit filed in the Northern District of Illinois claims the drugmaker “repeatedly raised the publicly listed price paid by consumers, while offering pharmacy benefit managers lower, undisclosed net prices,” and then pocketed the difference. AbbVie faces 38 counts of fraud-related claims across various states, according to the filing.
Since the drug hit the market in 2003, the repeated price hikes have added up to what now, in 2023, totals around $72,000 per year, the lawsuit claims, which “defies state laws prohibiting unfair and unreasonable prices,” and hurts consumers since “many Humira patients simply can’t afford it.”
In its 20 years on the market, Humira has had 27 price hikes, according to the press release from the filing law firm Hagens Berman. On top of that, in 2020, Humira reportedly allowed AbbVie to earn $16 billion in revenue.
Becker’s reached out to AbbVie for comment. This story will be updated if more information becomes available.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
